1. Home
  2. LXEH vs JAGX Comparison

LXEH vs JAGX Comparison

Compare LXEH & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lixiang Education Holding Co. Ltd.

LXEH

Lixiang Education Holding Co. Ltd.

HOLD

Current Price

$1.43

Market Cap

2.4M

Sector

Real Estate

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.69

Market Cap

2.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LXEH
JAGX
Founded
2001
2013
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.2M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
LXEH
JAGX
Price
$1.43
$2.69
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
389.4K
60.8K
Earning Date
05-01-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
N/A
N/A
Revenue
N/A
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.22
52 Week High
$3.28
$8.00

Technical Indicators

Market Signals
Indicator
LXEH
JAGX
Relative Strength Index (RSI) 58.11 47.74
Support Level $0.21 $1.74
Resistance Level $1.54 $4.13
Average True Range (ATR) 0.28 0.29
MACD -0.03 -0.13
Stochastic Oscillator 27.54 15.52

Price Performance

Historical Comparison
LXEH
JAGX

About LXEH Lixiang Education Holding Co. Ltd.

Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: